Investment firm Barclays laid out its thoughts for the technology space in 2025 in a research note on Thursday. Read for more ...

Discover how the S&P 500 Index performed in 2024 and what that could mean for the first quarter of 2025 according to Barclays ...

China, the global growth engine for the last 20 years, now boasts lower long-term bond yields than Japan, the former poster ...

Barclays Plc’s Stephen Dainton is preparing for a wave of dealmaking this year as more US companies have been buoyed by ...

Emmanuel Cau, head of European equity strategy at Barclays, weighs in on the outlook for European stocks in 2025.

Barclays PLC BARC shares slid 2.60% to £2.66 Tuesday, on what proved to be an all-around grim trading session for the stock ...

From China to Europe, Canada to Mexico, world markets are already reeling from Donald Trump's promise to jack up tariffs when ...

Simple volatility is the biggest risk for retail investors. Crypto coins, tokens, and currencies are “purely speculative,” ...

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

Barclays raised its price target on Ulta Beauty Inc (NASDAQ:ULTA) to $445 from $410 on stronger-than-expected preliminary ...

In a report released today, Seth Sigman from Barclays maintained a Hold rating on Five Below (FIVE – Research Report), with a price target of ...

On Wednesday, Barclays PLC (BCS) stock saw a decline, ending the day at $13.19 which represents a decrease of $-0.06 or -0.45% from the prior close of $13.25. The stock opened at $13.01 and touched a ...